The BEACON CRC study (NCT02928224; Binimetinib, Encorafenib and Cetuximab Combined to Treat BRAF-Mutant Colorectal Cancer) demonstrated that the BRAF inhibitor Enco plus the anti-epidermal growth factor receptor (EGFR) antibody Cetux, with or without the MEK inhibitor Bini, improved OS, objective response rate and progression-free survival (PFS) compared with Cetux plus chemotherapy in patients with BRAF-V600E-mutant mCRC who had been previously treated3,4. The gene discussed is EGFR; the disease is colorectal cancer.